PressOctober 7, 2022 Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Market ResearchOctober 6, 2022 The MindMed Chronicles: Part 2 of the Interview with Jake Freeman of Freeman Capital
PressOctober 6, 2022 Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
PressOctober 6, 2022 Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial
PressOctober 5, 2022 Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
BlogOctober 5, 2022 Gregory Roufa and David Glowacki are Building Digital Group Therapeutics – Podcast Episode #20
PressOctober 5, 2022 PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
PressOctober 5, 2022 Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
PressOctober 4, 2022 Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings
PressOctober 4, 2022 PSYC Corporation Discusses Significance of Expansion into Cannabis and Precious Metals Sectors with The Stock Day Podcast
PressOctober 4, 2022 Irwin Naturals Agrees to Add Idaho Clinic to Its National Chain of Psychedelic Mental-Health Clinics
PressOctober 4, 2022 MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
PressOctober 4, 2022 PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA
PressOctober 4, 2022 KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers
